| 4.62 0.29 (6.7%) | 12-15 15:59 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 5.62 | 1-year : | 6.56 |
| Resists | First : | 4.81 | Second : | 5.62 |
| Pivot price | 4.41 |
|||
| Supports | First : | 3.67 |
Second : | 2.97 |
| MAs | MA(5) : | 4.54 |
MA(20) : | 4.1 |
| MA(100) : | 3.28 |
MA(250) : | 0 | |
| MACD | MACD : | 0.3  |
Signal : | 0.3 |
| %K %D | K(14,3) : | 82.9 |
D(3) : | 84.3 |
| RSI | RSI(14): 65 |
|||
| 52-week | High : | 4.81 | Low : | 1.41 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ CALC ] has closed below upper band by 25.7%. Bollinger Bands are 20.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 4.67 - 4.7 | 4.7 - 4.72 |
| Low: | 4.19 - 4.21 | 4.21 - 4.23 |
| Close: | 4.58 - 4.62 | 4.62 - 4.66 |
CalciMedica, Inc., a clinical-stage biotechnology company, focuses on developing therapies for life-threatening inflammatory diseases with unmet needs. Its proprietary technology targets the inhibition of calcium release-activated (CRAC) channels designs to modulate the immune response and protect against tissue cell injury in life-threatening inflammatory diseases. Its lead product candidate is Auxora, a proprietary intravenous-formulated CRAC channel inhibitor for the treatment of acute pancreatitis, asparaginase-associated acute pancreatitis, and acute kidney injury. The company is based in La Jolla, California.
Fri, 05 Dec 2025
Stonepine Capital Management LLC Has $136,000 Stock Position in CalciMedica Inc. $CALC - MarketBeat
Fri, 21 Nov 2025
From Calcium Channels To Cash Runway: Why CalciMedica Is A Stock To Watch - RTTNews
Mon, 10 Nov 2025
CalciMedica Presents Data from Preclinical Study of Auxora™ in an Animal Model of AKI at ASN Kidney Week 2025 - PR Newswire
Tue, 12 Aug 2025
CalciMedica Reports Second Quarter 2025 Financial Results and Provides Clinical & Corporate Updates - PR Newswire
Sat, 19 Jul 2025
CalciMedica’s Clinical Gambit Reflects Biotech’s High-Risk, High-Reward Reality - Finimize
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 14 (M) |
| Shares Float | 6 (M) |
| Held by Insiders | 28.2 (%) |
| Held by Institutions | 55.6 (%) |
| Shares Short | 64 (K) |
| Shares Short P.Month | 56 (K) |
| EPS | -1.63 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.02 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -100.1 % |
| Return on Equity (ttm) | -526.4 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.73 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -21 (M) |
| Levered Free Cash Flow | -13 (M) |
| PE Ratio | -2.86 |
| PEG Ratio | 0 |
| Price to Book value | -231 |
| Price to Sales | 0 |
| Price to Cash Flow | -3.13 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|